Why Is GLSI Stock Rising Today?

Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.
Trending stock
Stock chart (Image Courtesy: Getty Images)
Profile Image
Rounak Jain·Stocktwits
Published Mar 17, 2026   |   6:41 AM EDT
Share
·
Add us onAdd us on Google

Greenwich LifeSciences Inc. (GLSI) shares gained more than 13% in Tuesday’s pre-market trade after the company announced that its immunotherapy trial has shown a continued reduction in the rate of recurrence of breast cancer.

Greenwich LifeSciences said its 250-patient Phase III breast cancer immunotherapy trial, FLAMINGO-01, showed an annual recurrence rate below 1%.

Retail sentiment on Stocktwits around Greenwich LifeSciences trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels. GLSI was the top trending ticker on the platform at the time of writing.

Get updates to this story developing directly on Stocktwits.

Also See: Trump Says Fed Chair Powell Should Cut Rates Right Now

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy